<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03866577</url>
  </required_header>
  <id_info>
    <org_study_id>CR108979</org_study_id>
    <secondary_id>2018-003534-32</secondary_id>
    <secondary_id>MOM-M254-001</secondary_id>
    <nct_id>NCT03866577</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients</brief_title>
  <official_title>A 4-part Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of M254 in Healthy Volunteers and in Patients With Immune Thrombocytopenic Purpura</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Momenta Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Momenta Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety, tolerability, pharmacokinetics, and&#xD;
      pharmacodynamics of M254 after administration of a single ascending dose and repeat doses in&#xD;
      healthy volunteers and immune thrombocytopenic purpura (ITP) patients. The pharmacodynamics&#xD;
      of the drug will be measured as platelet response in patients with ITP.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Part A of the study is currently not accepting healthy volunteers as the recruitment for&#xD;
      the part A has completed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was terminated based on Sponsor decision.&#xD;
  </why_stopped>
  <start_date type="Actual">December 21, 2018</start_date>
  <completion_date type="Actual">June 9, 2021</completion_date>
  <primary_completion_date type="Actual">June 9, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Part A: Double (Subject, Investigator);&#xD;
Part B, C, and D: Open Label Investigations</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number and Severity of Adverse Events (AEs) - Part A</measure>
    <time_frame>Up to approximately Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Clinically Significant Abnormalities in Clinical Safety Laboratory Values - Part A</measure>
    <time_frame>Up to approximately Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Shift From Baseline in Clinically Significant Abnormalities for Clinical Safety Laboratory Values - Part A</measure>
    <time_frame>Up to approximately Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Clinically Significant Abnormalities in Vital Signs - Part A</measure>
    <time_frame>Up to approximately Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Shift From Baseline in Clinically Significant Abnormalities for Vital Signs - Part A</measure>
    <time_frame>Up to approximately Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Clinically Significant Abnormalities in Electrocardiograms (ECGs) - Part A</measure>
    <time_frame>Up to approximately Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Shift From Baseline in Clinically Significant Abnormalities for Electrocardiograms (ECGs) - Part A</measure>
    <time_frame>Up to approximately Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and Severity of AEs - Part B</measure>
    <time_frame>Up to approximately Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Clinically Significant Abnormalities in Clinical Safety Laboratory Values - Part B</measure>
    <time_frame>Up to approximately Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Shift From Baseline in Clinically Significant Abnormalities for Clinical Safety Laboratory Values - Part B</measure>
    <time_frame>Up to approximately Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Clinically Significant Abnormalities in Vital Signs - Part B</measure>
    <time_frame>Up to approximately Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Shift From Baseline in Clinically Significant Abnormalities for Vital Signs - Part B</measure>
    <time_frame>Up to approximately Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Clinically Significant Abnormalities in ECGs - Part B</measure>
    <time_frame>Up to approximately Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Shift From Baseline in Clinically Significant Abnormalities for ECGs - Part B</measure>
    <time_frame>Up to approximately Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and Severity of AEs - Part C</measure>
    <time_frame>Up to approximately Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Clinically Significant Abnormalities in Clinical Safety Laboratory Values - Part C</measure>
    <time_frame>Up to approximately Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Shift From Baseline in Clinically Significant Abnormalities for Clinical Safety Laboratory Values - Part C</measure>
    <time_frame>Up to approximately Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Clinically Significant Abnormalities in Vital Signs - Part C</measure>
    <time_frame>Up to approximately Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Shift From Baseline in Clinically Significant Abnormalities for Vital Signs - Part C</measure>
    <time_frame>Up to approximately Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Clinically Significant Abnormalities in ECGs - Part C</measure>
    <time_frame>Up to approximately Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Shift From Baseline in Clinically Significant Abnormalities for ECGs - Part C</measure>
    <time_frame>Up to approximately Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of Changes in Platelet Counts After M254 Administration Compared to IVIg - Part C</measure>
    <time_frame>Baseline to approximately Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and Severity of AEs - Part D</measure>
    <time_frame>Up to approximately Day 71</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Clinically Significant Abnormalities in Clinical Safety Laboratory Values - Part D</measure>
    <time_frame>Up to approximately Day 71</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Shift From Baseline in Clinically Significant Abnormalities for Clinical Safety Laboratory Values - Part D</measure>
    <time_frame>Up to approximately Day 71</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Clinically Significant Abnormalities in Vital Signs - Part D</measure>
    <time_frame>Up to approximately Day 71</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Shift From Baseline in Clinically Significant Abnormalities for Vital Signs - Part D</measure>
    <time_frame>Up to approximately Day 71</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Clinically Significant Abnormalities in ECGs - Part D</measure>
    <time_frame>Up to approximately Day 71</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Shift From Baseline in Clinically Significant Abnormalities for ECGs - Part D</measure>
    <time_frame>Up to approximately Day 71</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of M254 - Part A, B, and C</measure>
    <time_frame>Day 1 to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of M254 - Part A, B, and C</measure>
    <time_frame>Day 1 to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Zero to Time of Last Measurable Concentration Area [AUC(0 last)] of M254 - Part A, B, and C</measure>
    <time_frame>Day 1 to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Zero to Infinity [AUC(0 âˆž)] of M254 - Part A, B, and C</measure>
    <time_frame>Day 1 to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (Vd) of M254 - Part A, B, and C</measure>
    <time_frame>Day 1 to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of Drug (CL) M254 - Part A, B, and C</measure>
    <time_frame>Day 1 to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time (MRT) of M254 - Part A, B, and C</measure>
    <time_frame>Day 1 to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal-phase Half-life (tÂ½) of M254 - Part A, B, and C</measure>
    <time_frame>Day 1 to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of M254 - Part D</measure>
    <time_frame>Day 1 to Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of M254 - Part D</measure>
    <time_frame>Day 1 to Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0 last) of M254 - Part D</measure>
    <time_frame>Day 1 to Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0 âˆž) of M254 - Part D</measure>
    <time_frame>Day 1 to Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd of M254 - Part D</measure>
    <time_frame>Day 1 to Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL of M254 - Part D</measure>
    <time_frame>Day 1 to Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT of M254 - Part D</measure>
    <time_frame>Day 1 to Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tÂ½ of M254 - Part D</measure>
    <time_frame>Day 1 to Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurements of Changes in Platelet Counts After M254 Administration - Part D</measure>
    <time_frame>Baseline to approximately Day 71</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Immune Thrombocytopenic Purpura (ITP)</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive a single ascending dose of M254 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immune thrombocytopenic purpura (ITP) patients will receive a single ascending dose of M254 followed by IVIg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ITP patients will receive a single dose of M254 or IVIg, followed by a single dose of the other drug approximately 28 days later</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ITP patients will receive repeated doses of M254</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological: M254</intervention_name>
    <description>M254 administered as intravenous infusion</description>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_label>Part C</arm_group_label>
    <arm_group_label>Part D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered as intravenous infusion</description>
    <arm_group_label>Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intravenous immunoglobulin (IVIg)</intervention_name>
    <description>IVIg administered as intravenous infusion</description>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_label>Part C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Criteria for Healthy Volunteers: Subject must be between the ages of 18 and 55 years;&#xD;
        healthy as indicated by medical history, physical examination, vital signs, clinical&#xD;
        laboratory tests, and 12-lead electrocardiogram, and all abnormal findings are assessed as&#xD;
        not clinically significant by the Investigator; not pregnant or breastfeeding; and no other&#xD;
        clinically relevant abnormalities currently or in their history that the Investigator would&#xD;
        deem them ineligible to participate.&#xD;
&#xD;
        Key Criteria for Immune Thrombocytopenic Purpura (ITP) Patients: Patient must be aged â‰¥18&#xD;
        years and diagnosed with ITP at least 3 months prior to screening, stable maintenance&#xD;
        therapy for at least 4 weeks prior to the first study visit, not pregnant or breastfeeding,&#xD;
        and no other clinically relevant abnormalities currently or in their history that the&#xD;
        Investigator would deem them ineligible to participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Momenta General Queries</last_name>
    <role>Study Director</role>
    <affiliation>Momenta Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Institute of Hope and Innovation</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakes Research</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taussig Cancer Insititute - Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucl de Mont-Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somogy Megyei Kaposi Mor Oktato Korhaz</name>
      <address>
        <city>Kaposvar</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem</name>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Unita Sanitaria Locale di Ravenna</name>
      <address>
        <city>Ravenna</city>
        <zip>48100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova - IRCCS</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale 'Casa Sollievo della Sofferenza' - U.O. Ematologia-</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Groningen</city>
        <zip>NZ 9728</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silesian Healthy Blood Clinic</name>
      <address>
        <city>Chorzow</city>
        <zip>41-503</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 1</name>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewodzki w Opolu</name>
      <address>
        <city>Opole</city>
        <zip>45-061</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny ZakÅ‚ad Opieki Zdrowotnej MSW w Poznaniu im. prof. Ludwika Bierkowskiego</name>
      <address>
        <city>Poznan</city>
        <zip>60-631</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Vall D Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. de Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Carlos Haya</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Gral. Univ. J.M. Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Clinico Univ. de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>Germany</country>
  </removed_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2019</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immune thrombocytopenic purpura</keyword>
  <keyword>Healthy subjects</keyword>
  <keyword>M254</keyword>
  <keyword>Intravenous immunoglobulin (IVIg)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

